Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22021450 | 0.86 | CYP2E1 (0.32) | KMT2A | |
| SCHEMBL16361029 | 0.80 | KMT2A (0.35) | KMT2A | |
| SCHEMBL25753722 | 0.80 | SOST (0.34) | KMT2A | |
| SCHEMBL25638707 | 0.77 | SMN1; SMN2 (0.37) | KMT2ASMN1; SMN2 | |
| SCHEMBL24972953 | 0.77 | DDB1 (0.33) | KMT2ASMN1; SMN2 | |
| SCHEMBL22021349 | 0.75 | SQOR (0.40) | SMN1; SMN2 | |
| SCHEMBL12369390 | 0.73 | PDE2A (0.33) | KMT2A | |
| SCHEMBL25823753 | 0.72 | TK1 (0.40) | KMT2ASMN1; SMN2 | |
| SCHEMBL22020905 | 0.71 | — | — | |
| SCHEMBL25753716 | 0.71 | TLR8 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257414-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-08-17 | — | — | US | disclosed |
| US-20230203083-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257414-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | KMT2A 1334/4885SMN1; SMN2 1787/4885 |
| US-20230203083-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | KMT2A 1334/4885SMN1; SMN2 1787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.